Nothing Special   »   [go: up one dir, main page]

MASS, 2022 - Google Patents

2022 NATIONAL CONGRESS OF THE ITALIAN SOCIETY OF HYPERTENSION (SIIA)

MASS, 2022

View PDF
Document ID
11063867492086272049
Author
MASS L
Publication year

External Links

Snippet

Methods: We analysed data from 1892 subjects of the PAMELA study with available UA, lipids (total cholesterol, HDL, LDL, non-HDL, triglycerides) and variables needed to calculate VAI, Cardio-Metabolic Index (CMI) and Lipid Accumulation Product (LAP). Results …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes

Similar Documents

Publication Publication Date Title
Vasan et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort
Pepine et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia: results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study
Fourie et al. Is HIV-1 infection associated with endothelial dysfunction in a population of African ancestry in South Africa?: Cardiovascular topics
Yamamoto et al. Prognostic significance of circulating leukocyte subtype counts in patients with coronary artery disease
Pär et al. Circadian blood pressure variation in patients with type 2 diabetes–relationship to macro-and microvascular subclinical organ damage
Kasahara et al. Conversion formula from B-type natriuretic peptide to N-terminal proBNP values in patients with cardiovascular diseases
Ślubowska et al. Left ventricular hypertrophy in renal transplant recipients in the first year after transplantation
Suzuki et al. Assessment of transthyretin combined with mini nutritional assessment on admission provides useful prognostic information in patients with acute decompensated heart failure
Vallée Association between serum uric acid and arterial stiffness in a large‐aged 40–70 years old population
Arrieta et al. Soluble ST2 levels are related to replacement myocardial fibrosis in severe aortic stenosis
Okumura et al. Association between cardiopulmonary exercise and dobutamine stress testing in ambulatory patients with idiopathic dilated cardiomyopathy: a comparison with peak VO2 and VE/VCO2 slope
El-Makrem et al. The role of platelets CD40 ligand (CD154) in acute coronary syndromes
MASS 2022 NATIONAL CONGRESS OF THE ITALIAN SOCIETY OF HYPERTENSION (SIIA)
Wang et al. Lipoprotein (a) is associated with left ventricular systolic dysfunction in a Chinese population of patients with hypertension and without coronary artery disease
Beltrami-Moreira et al. Association between plasma adiponectin and arteriolar vessel caliber among elderly hypertensive subjects
Zhao et al. High-sensitivity C-reactive protein predicts target organ damage in Chinese patients with metabolic syndrome
OBESE 2023 National Congress of the Italian Society of Hypertension (SIIA)
Paine et al. Assessment and management of patients with portopulmonary hypertension undergoing liver transplantation
Loboda et al. Cardiac status and atherosclerotic cardiovascular risk of convalescents after COVID-19 in Poland
Pefani Association of plasma renin and aldosterone concentration and its ratio with systolic and diastolic cardiac function and phenotypes of cardiac disorder
Erina et al. INITIATION OF ANTIHYPERTENSIVE THERAPY BASED ON CURRENT HYPERTENSION GUIDELINE–DO AMERICAN AND EUROPEAN APPROACH DIFFER?
Faconti et al. DOES ETHNICITY INFLUENCE THE RELATIONSHIP BETWEEN ALDOSTERONE AND EARLY SIGN OF CARDIAC REMODELLING? A CARDIOVASCULAR MAGNETIC RESONANCE STUDY
Huda et al. Predictive value of gamma-glutamyltransferase and neutrophil lymphocyte ratio for postoperative complications following emergency surgery
Presta PULSE WAVE VELOCITY, IPERTENSIONE E LIVELLI DI ALDOSTERONE PLASMATICO
Ogawa et al. A2691 Anti-hypertensive effect of thermolysin-digested rice bran on high normal blood pressure and mild hypertension